It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Parasitic nematodes infect one quarter of the world’s population and impact all humans through widespread infection of crops and livestock. Resistance to current anthelmintics has prompted the search for new drugs. Traditional screens that rely on parasitic worms are costly and labour intensive and target-based approaches have failed to yield novel anthelmintics. Here, we present our screen of 67,012 compounds to identify those that kill the non-parasitic nematode Caenorhabditis elegans. We then rescreen our hits in two parasitic nematode species and two vertebrate models (HEK293 cells and zebrafish), and identify 30 structurally distinct anthelmintic lead molecules. Genetic screens of 19 million C. elegans mutants reveal those nematicides for which the generation of resistance is and is not likely. We identify the target of one lead with nematode specificity and nanomolar potency as complex II of the electron transport chain. This work establishes C. elegans as an effective and cost-efficient model system for anthelmintic discovery.
Screening for new anthelmintic compounds that are active against parasitic nematodes is costly and labour intensive. Here, the authors use the non-parasitic nematode Caenorhabditis elegansto identify 30 anthelmintic lead compounds in an effective and cost-efficient manner.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 The Donnelly Centre for Cellular and Biomolecular Research, University of Toronto, Toronto, Canada (GRID:grid.17063.33) (ISNI:0000 0001 2157 2938)
2 The Donnelly Centre for Cellular and Biomolecular Research, University of Toronto, Toronto, Canada (GRID:grid.17063.33) (ISNI:0000 0001 2157 2938); University of Toronto, Department of Molecular Genetics, Toronto, Canada (GRID:grid.17063.33) (ISNI:0000 0001 2157 2938)
3 Brigham and Women’s Hospital, Harvard Medical School, and Harvard Stem Cell Institute, Cardiovascular Division, Boston, USA (GRID:grid.17063.33); Harvard Medical School, Department of Medicine, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X)
4 Faculty of Veterinary Medicine, University of Calgary, Department of Comparative Biology and Experimental Medicine, Calgary, Canada (GRID:grid.22072.35) (ISNI:0000 0004 1936 7697)
5 University of Toronto, 1 King's College Circle, Department of Biochemistry, Toronto, Canada (GRID:grid.17063.33) (ISNI:0000 0001 2157 2938)
6 University of California, Center for Discovery and Innovation in Parasitic Diseases and Department of Pathology, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811)
7 Center for Plant Cell Biology, University of California, Department of Botany and Plant Sciences, Riverside, USA (GRID:grid.266097.c) (ISNI:0000 0001 2222 1582)
8 Institute for Research in Immunology and Cancer, University of Montreal, Montreal, Canada (GRID:grid.14848.31) (ISNI:0000 0001 2292 3357)
9 University of British Columbia, Department of Pharmaceutical Sciences, Vancouver, Canada (GRID:grid.17091.3e) (ISNI:0000 0001 2288 9830)
10 The Donnelly Centre for Cellular and Biomolecular Research, University of Toronto, Toronto, Canada (GRID:grid.17063.33) (ISNI:0000 0001 2157 2938); University of Toronto, Department of Molecular Genetics, Toronto, Canada (GRID:grid.17063.33) (ISNI:0000 0001 2157 2938); University of Toronto, Department of Pharmacology and Toxicology, Toronto, Canada (GRID:grid.17063.33) (ISNI:0000 0001 2157 2938)